1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
General Anesthesia Drugs Market By TYPE OF DRUGS, By ROUTE OF ADMNISTRATION, By SURGERY TYPE, By END USER : Global Opportunity Analysis and Industry Forecast, 2021-2031

General Anesthesia Drugs Market By TYPE OF DRUGS, By ROUTE OF ADMNISTRATION, By SURGERY TYPE, By END USER : Global Opportunity Analysis and Industry Forecast, 2021-2031

  • May 2022
  • 284 pages
  • ID: 6311594
  • Format: PDF
  • Allied Market Research

Summary

Table of Contents

General Anesthesia Drugs Market By TYPE OF DRUGS (Propofol, Sevoflurane, Desflurane, Others), By ROUTE OF ADMNISTRATION (Intravenous, Inhalation), By SURGERY TYPE (Knee and hip replacements, Heart surgeries, Cancer surgery, General surgery), By END USER (Hospital, Ambulatory surgical centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

The general anesthesia drug market was valued at $5,400.5 million in 2021, and is projected to reach $7,736.3 million by 2031, registering a CAGR of 3.5% from 2022 to 2031. General anesthesia is a combination of medication which causes sleep-like state before a surgery or other medical procedure. Under general anesthesia patient does not feel pain because patient is completely in unconscious state. General anesthesia is given with the combination of intravenous and inhalation anesthesia drugs. There are many equipment specifically designed for different surgical procedures. These include anesthetic vaporizer that is used as a vaporizing anesthetic; nasal oxygen set for delivering oxygen and others.  Some intravenous drugs such as propofol, etomidate, and ketamine are intravenous sedative hypotonic agents which are given in general anesthesia. Sevoflurane and desflurane are inhalation general anesthesia drugs which are used during surgical procedure.
The general anesthesia drug market is majorly driven by increase in number of surgical procedures like hip and knee replacement surgery, cardiac surgery, general surgeries cancer surgeries, rise in number of geriatric population, increase in prevalence of osteoarthritis disease, and neurological disorder. Moreover increase in number of key players to formulate general anesthesia drug, propels the growth of the market. According to the rheumatology advisor, the annual number of total knee arthroplasty was predicted to increase by 56% from 2019 to 2020. The demand for general anesthesia increases due to an increase in the number of knee arthroplasty surgery procedures. The knee and hip replacement procedures are majorly conducted under general anesthesia. Increase in prevalence of chronic disease, such as cardiovascular disease, cancer, and others is one of the major factor that boosts the growth of the market. According to the Centers for disease control and prevention (CDC) approximately 659,000 population in the U.S. experienced death from heart disease each year. According to the same report in 2019, a total of 360,900 people died due to coronary heart disease. Every year in the U.S. approximately 805,000 population are diagnosed with heart attack among which 605,000 experienced their first heart attack. This factor upsurges the need for heart surgery, which further increases the need for general anesthesia.
On the contrary, risk associated with general anesthesia such as allergic reaction, nausea, and vomiting is anticipated to hinder the market growth during the forecast period. Advancement in R&D activities in general anesthesia in pharmaceutical and biotechnology sector propels the growth of the market. Rise in funding from government or non-government organization to provide surgical resources, encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the general anesthesia drug market.
The general anesthesia drug market is segmented into type of drug, route of administration, surgery type, end user, and region. By type of drug, the market is categorized into propofol, sevoflurane, desflurane and other. Further the others segment is studied under ketamine, thiopental, methohexital, etomidate, isoflurane, and fospropofol. By route of administration, the market is bifurcated into intravenous and inhalation. By surgery, the market is divided into knee & hip replacements, heart surgeries, cancer surgery, and general surgery. By end user the market is classified into hospital and ambulatory surgical centers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the general anesthesia drug market are AbbVie, AstraZeneca, Avet Pharmaceuticals Inc. B. Braun Melsungen, Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, PAION AG, Abbott, and Pfizer.
 

Key Benefits For Stakeholders
?This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the general anesthesia drugs market analysis from 2021 to 2031 to identify the prevailing general anesthesia drugs market opportunity.
?The market research is offered along with information related to key drivers, restraints, and opportunities.
?Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
?In-depth analysis of the general anesthesia drugs market segmentation assists to determine the prevailing market opportunities.
?Major countries in each region are mapped according to their revenue contribution to the global market.
?Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
?The report includes the analysis of the regional as well as global general anesthesia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By TYPE OF DRUGS
? Propofol
? Sevoflurane
? Desflurane
? Others

By ROUTE OF ADMNISTRATION
? Intravenous
? Inhalation

By SURGERY TYPE
? Knee and hip replacements
? Heart surgeries
? Cancer surgery
? General surgery

By END USER
? Hospital
? Ambulatory surgical centers

By Region
? North America
? U.S.
? Canada
? Mexico
? Europe
? Germany
? France
? U.K.
? Italy
? Spain
? Rest of Europe
? Asia-Pacific
? China
? Japan
? India
? Australia
? South Korea
? Rest of Asia-Pacific
? LAMEA
? Brazil
? Saudi Arabia
? South Africa
? Rest of LAMEA
? Key Market Players
? B. Braun Melsungen
? Baxter International Inc.
? Fresenius SE and Co. KGaA
? Hikma Pharmaceuticals plc
? Paion AG
? Pfizer Inc.
? Abbott Laboratories
? Abbvie Inc
? AstraZeneca plc
? Avet Pharmaceuticals Inc

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Local Anesthesia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

  • $ 2499
  • August 2022
  • 143 pages

The global local anesthesia drugs market size reached US$ 2.77 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 3.62 Billion by 2027, exhibiting a growth rate (CAGR) of 4.30% ...

  • World
  • Hospital
  • Anesthetics
  • Industry analysis
  • Surgical Procedures Performed

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on